Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Therapy for cystic fibrosis--the end of the beginning?

Davis PB.

N Engl J Med. 2011 Nov 3;365(18):1734-5. doi: 10.1056/NEJMe1110323. No abstract available.

PMID:
22047565
2.

Cystic fibrosis transmembrane conductance regulator biomarkers in 'real life': can we evaluate individual efficacy of cystic fibrosis transmembrane conductance regulator therapy?

van Koningsbruggen-Rietschel S, Naehrlich L.

Ther Adv Respir Dis. 2015 Aug;9(4):198-200. doi: 10.1177/1753465815579364. No abstract available.

PMID:
26175480
3.

Mutation-specific therapy in cystic fibrosis: the earlier, the better.

Tümmler B.

Lancet Respir Med. 2013 Oct;1(8):591-592. doi: 10.1016/S2213-2600(13)70186-3. Epub 2013 Sep 10. No abstract available.

PMID:
24461654
4.

Targeting the basic defect in cystic fibrosis.

Welsh MJ.

N Engl J Med. 2010 Nov 18;363(21):2056-7. doi: 10.1056/NEJMe1010123. No abstract available.

PMID:
21083391
5.

Ivacaftor in a G551D homozygote with cystic fibrosis.

Harrison MJ, Murphy DM, Plant BJ.

N Engl J Med. 2013 Sep 26;369(13):1280-2. doi: 10.1056/NEJMc1213681. No abstract available.

6.

Intestinal Current Measurements Detect Activation of Mutant CFTR in Patients with Cystic Fibrosis with the G551D Mutation Treated with Ivacaftor.

Graeber SY, Hug MJ, Sommerburg O, Hirtz S, Hentschel J, Heinzmann A, Dopfer C, Schulz A, Mainz JG, Tümmler B, Mall MA.

Am J Respir Crit Care Med. 2015 Nov 15;192(10):1252-5. doi: 10.1164/rccm.201507-1271LE. No abstract available.

PMID:
26568242
7.

Cystic fibrosis drug Vertex's latest triumph.

Ledford H.

Nat Biotechnol. 2012 Mar 7;30(3):201-2. doi: 10.1038/nbt0312-201a. No abstract available.

PMID:
22398597
8.

A combination therapy for cystic fibrosis.

Brodsky JL, Frizzell RA.

Cell. 2015 Sep 24;163(1):17. doi: 10.1016/j.cell.2015.09.003.

9.

Treating Specific Variants Causing Cystic Fibrosis.

Cutting GR.

JAMA. 2017 Dec 5;318(21):2130-2131. doi: 10.1001/jama.2017.16823. No abstract available.

PMID:
29209709
10.

Personalized medicine. New cystic fibrosis drug offers hope, at a price.

Kaiser J.

Science. 2012 Feb 10;335(6069):645. doi: 10.1126/science.335.6069.645. No abstract available. Erratum in: Science. 2012 Feb 24;335(6071):918.

PMID:
22323790
11.

Excitement mounts for first disease-modifying cystic fibrosis drugs.

Opar A.

Nat Rev Drug Discov. 2011 Jul 1;10(7):479-80. doi: 10.1038/nrd3488. No abstract available.

PMID:
21720393
12.

Response to: 'Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?' by Jones and Barry.

Elborn JS, Ramsey B, Wainwright C, Boyle M.

Thorax. 2016 Feb;71(2):185-6. doi: 10.1136/thoraxjnl-2015-207611. Epub 2015 Oct 27. No abstract available.

PMID:
26506855
13.

Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?

Jones AM, Barry PJ.

Thorax. 2015 Jul;70(7):615-6. doi: 10.1136/thoraxjnl-2015-207369. No abstract available.

PMID:
26071414
14.

Potentiators for cystic fibrosis - targeting the underlying molecular defect.

Patel S, Sinha IP, Dwan K, Echevarria C, Schechter M, Southern KW.

Paediatr Respir Rev. 2015 Jun;16(3):162-4. doi: 10.1016/j.prrv.2015.04.003. Epub 2015 Apr 20. Review. No abstract available.

PMID:
26002404
15.

Cystic fibrosis transmembrane conductance regulator dysfunction and its treatment.

Hull J.

J R Soc Med. 2012 Jun;105 Suppl 2:S2-8. doi: 10.1258/jrsm.2012.12s001. Review. No abstract available.

16.

[Causal therapy is available].

Meißner T.

MMW Fortschr Med. 2016 Jun 23;158(12):74. doi: 10.1007/s15006-016-8458-8. German. No abstract available.

PMID:
27324018
17.

Pulmonology: CFTR modulators for cystic fibrosis.

Bertoncini E, Colomb-Lippa D.

JAAPA. 2013 Feb;26(2):59-60. No abstract available.

PMID:
23409389
18.

Ivacaftor.

Davis PB, Yasothan U, Kirkpatrick P.

Nat Rev Drug Discov. 2012 Apr 30;11(5):349-50. doi: 10.1038/nrd3723. No abstract available.

PMID:
22543461
19.

PharmGKB summary: very important pharmacogene information for CFTR.

McDonagh EM, Clancy JP, Altman RB, Klein TE.

Pharmacogenet Genomics. 2015 Mar;25(3):149-56. doi: 10.1097/FPC.0000000000000112. No abstract available.

20.

Aquagenic wrinkling of the palms in a patient with cystic fibrosis.

Grasemann H, Ratjen F, Solomon M.

N Engl J Med. 2013 Dec 12;369(24):2362-3. doi: 10.1056/NEJMc1308349. No abstract available.

Supplemental Content

Support Center